PMID- 33802165
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 6
DP  - 2021 Mar 10
TI  - Arterial Blood Pressure Variability and Other Vascular Factors Contribution to 
      the Cognitive Decline in Parkinson's Disease.
LID - 10.3390/molecules26061523 [doi]
LID - 1523
AB  - Dementia is one of the most disabling non-motor symptoms in Parkinson's disease 
      (PD). Unlike in Alzheimer's disease, the vascular pathology in PD is less 
      documented. Due to the uncertain role of commonly investigated metabolic or 
      vascular factors, e.g., hypertension or diabetes, other factors corresponding to 
      PD dementia have been proposed. Associated dysautonomia and dopaminergic 
      treatment seem to have an impact on diurnal blood pressure (BP) variability, 
      which may presumably contribute to white matter hyperintensities (WMH) 
      development and cognitive decline. We aim to review possible vascular and 
      metabolic factors: Renin-angiotensin-aldosterone system, vascular endothelial 
      growth factor (VEGF), hyperhomocysteinemia (HHcy), as well as the dopaminergic 
      treatment, in the etiopathogenesis of PD dementia. Additionally, we focus on the 
      role of polymorphisms within the genes for catechol-O-methyltransferase (COMT), 
      apolipoprotein E (APOE), vascular endothelial growth factor (VEGF), and for 
      renin-angiotensin-aldosterone system components, and their contribution to 
      cognitive decline in PD. Determining vascular risk factors and their contribution 
      to the cognitive impairment in PD may result in screening, as well as preventive 
      measures.
FAU - Pierzchlinska, Anna
AU  - Pierzchlinska A
AUID- ORCID: 0000-0002-1606-7918
AD  - Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian 
      Medical University, Aleja Powstancow Wlkp 72, 70-111 Szczecin, Poland.
FAU - Kwasniak-Butowska, Magdalena
AU  - Kwasniak-Butowska M
AD  - Division of Neurological and Psychiatric Nursing, Medical University of Gdansk, 
      Aleja Jana Pawla II 50, 80-462 Gdansk, Poland.
AD  - Department of Neurology, St Adalbert Hospital, Aleja Jana Pawla II 50, 80-462 
      Gdansk, Poland.
FAU - Slawek, Jaroslaw
AU  - Slawek J
AD  - Division of Neurological and Psychiatric Nursing, Medical University of Gdansk, 
      Aleja Jana Pawla II 50, 80-462 Gdansk, Poland.
AD  - Department of Neurology, St Adalbert Hospital, Aleja Jana Pawla II 50, 80-462 
      Gdansk, Poland.
FAU - Drozdzik, Marek
AU  - Drozdzik M
AUID- ORCID: 0000-0002-6191-7168
AD  - Department of Experimental and Clinical Pharmacology, Pomeranian Medical 
      University, Aleja Powstancow Wlkp 72, 70-111 Szczecin, Poland.
FAU - Bialecka, Monika
AU  - Bialecka M
AD  - Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian 
      Medical University, Aleja Powstancow Wlkp 72, 70-111 Szczecin, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210310
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (ApoE protein, human)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.1.1.6 (COMT protein, human)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
SB  - IM
MH  - Apolipoproteins E/genetics
MH  - Arterial Pressure/physiology
MH  - Catechol O-Methyltransferase/genetics/metabolism
MH  - Cognitive Dysfunction/blood/*physiopathology
MH  - Humans
MH  - Hyperhomocysteinemia/metabolism/physiopathology
MH  - Parkinson Disease/blood/*physiopathology
MH  - Renin-Angiotensin System/physiology
MH  - Risk Factors
MH  - Vascular Endothelial Growth Factor A/metabolism/physiology
MH  - White Matter/pathology
PMC - PMC8001922
OTO - NOTNLM
OT  - dementia
OT  - dysautonomia
OT  - genetic polymorphisms
OT  - levodopa
OT  - orthostatic hypotension
OT  - renin-angiotensin system
OT  - white matter hyperintensities
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/04 06:00
MHDA- 2021/05/11 06:00
PMCR- 2021/03/10
CRDT- 2021/04/03 01:10
PHST- 2021/02/14 00:00 [received]
PHST- 2021/03/08 00:00 [revised]
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/04/03 01:10 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2021/03/10 00:00 [pmc-release]
AID - molecules26061523 [pii]
AID - molecules-26-01523 [pii]
AID - 10.3390/molecules26061523 [doi]
PST - epublish
SO  - Molecules. 2021 Mar 10;26(6):1523. doi: 10.3390/molecules26061523.